MRKvsRPRX
Merck & Co IncvsRoyalty Pharma PLC. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.
Merck & Co Inc
$114.62
+15.57%
Royalty Pharma PLC
$49.64
+29.34%
60-day price, rebased to 100
Round-by-round
Valuation upside
-26.90% vs -57.50% to DCF fair value
Balance-sheet strength
Altman Z 4.02 vs 2.25
Fundamental quality
Piotroski 4.00 vs 5.00 (of 9)
Growth + margins
Rule-of-40 20.30 vs 109.80
60-day momentum
+1.10% vs +19.10% price return
Market-cap liquidity
$298.8B vs $27.1B
Verdict
Across6categories,the two names are evenly matched —3wins each. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.
Backtest a strategy onMRKorRPRX
Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.